Reproductive and Metabolic Abnormalities Associated with Bipolar Disorder and Its Treatment

REFERENCES

• Newberg A, Catapano L, Zarate C, Manji H. Neurobiology of bipolar disorder. Expert Rev Neurother 2008; 8: 93–110
   PubMedGoogle Scholar
• Rothschild A. Biology of depression. Med Clin North Am 1988; 72: 765–90
   PubMed Web of Science ®Google Scholar
• Rasgon N, Altshuler L, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 2000; 61: 173–8
   PubMedGoogle Scholar
• Rasgon N, Altshuler L, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246–59
   PubMed Web of Science ®Google Scholar
• Rasgon N, Bauer M, Glenn T, Elman S, Whybrow P. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord 2003; 5: 48–52
   PubMed Web of Science ®Google Scholar
• O'Donovan C, Kusumaker V, Gravess G, Bird D. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322–30
   PubMed Web of Science ®Google Scholar
• McIntyre R, Mancini D, McCann S, Srinivasan J, Kennedy S. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003; 5: 28–35
   PubMed Web of Science ®Google Scholar
• Akdeniz F, Taneli F, Noyan A, Yüncü Z, Vahip S. Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women?. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 115–21
   Google Scholar
• Rasgon N, Reynolds M, Elman S, et al. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord 2005; 89: 217–35
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen L, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59: 1078–86
   PubMed Web of Science ®Google Scholar
• Joffe H, Kim D, Foris J B, et al. Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls. J Clin Psychiatry 2006; 67: 297–304
   PubMed Web of Science ®Google Scholar
• Newcomer J. Antipsychotic medications; metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68(suppl 4)8–13
   PubMed Web of Science ®Google Scholar
• Masand P, Culpepper L, Henderson D, et al. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr 2005; 10(10 suppl 14)1–15
   Google Scholar
• Lofgren E, Tapanainen J, Koivunen R, Pakarinen A, Isojarvi J. Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Epilepsia 2006; 47: 1441–6
   PubMed Web of Science ®Google Scholar
• Banning M. Symptoms and treatments of polycystic ovary syndrome. J Br Nurs 2006; 15: 635–9
   Google Scholar
• Reynolds M, Sisk E, Rasgon N. Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. Curr Med Chem 2007; 14: 2799–812
   PubMed Web of Science ®Google Scholar
• Burt V, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord 2004; 6: 2–13
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. J Jpn Psychiatry Neurol 1993; 47: 825–42
   Google Scholar
• Isojarvi J, Laatikainen T, Pakarinen A, Juntunen K M, Myllyla V V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N J Engl Med 1993; 329: 1383–8
   PubMed Web of Science ®Google Scholar
• Isojarvi J, Rattya J, Myllyla V, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51
   PubMed Web of Science ®Google Scholar
• O'Donovan C, Kusumakar V, Graves G, Bird D. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322–30
   PubMed Web of Science ®Google Scholar
• Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. J Am Med 1995; 98: 33s–39s
   PubMedGoogle Scholar
• Morrell M J, Hayes F J, Sluss P M, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008; 64: 200–11
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Chengappa K N. Weight gain and metabolic issues of medicines used for bipolar disorder. Curr Psychiatry Rep 2007; 9: 521–8
   PubMedGoogle Scholar
• Elmslie J L, Silverstone J T, Mann J I, Williams S M, Romans S E. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61: 179–84
   PubMed Web of Science ®Google Scholar
• Cheskin L J, Bartlett S J, Zayas R, Twilley C H, Allison D B, Contoreggi C. Prescription medications: a modifiable contributor to obesity. South J Med 1999; 92: 898–904
   PubMedGoogle Scholar
• Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord 2008; 110: 149–55
   PubMed Web of Science ®Google Scholar
• Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006; 67: 1034–41
   PubMed Web of Science ®Google Scholar
• Bowden C L. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000; 61(suppl 9)35–40
   Google Scholar
• Peselow E D, Dunner D L, Fieve R R, Lautin A. Lithium carbonate and weight gain. J Affect Disord 1980; 2: 303–10
   PubMed Web of Science ®Google Scholar
• Bowden C, Calabrese J, McElroy S. A randomized, placebo-controlled 12 month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481–9
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980; 62: 193–200
   PubMed Web of Science ®Google Scholar
• Aronne L J, Segal K R. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003; 64(suppl 8)22–9
   PubMedGoogle Scholar
• Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain. Pharmacopsychiatry 1995; 28: 35–44
   PubMed Web of Science ®Google Scholar
• Livingstone C, Rampes H. Lithium: a review of its metabolic adverse effects. J Psychopharmacol 2006; 20: 347–55
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988; 78: 434–41
   PubMed Web of Science ®Google Scholar
• Vendsborg P B, Bech P, Rafaelsen O J. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53: 139–47
   PubMedGoogle Scholar
• Mathew B, Rao J, Sundari U. Lithium-induced changes in body mass index. Acta Psychiatr Scand 1976; 53: 355–9
   Google Scholar
• Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci 2002; 27: 104–7
   Google Scholar
• Levine S, Saltzman A. Lithium increases gastrointestinal tract weight of male or female rats but it increases body weight only in females. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 29–33
   Google Scholar
• van d er, Velde C, Gordon M. Manic-depressive illness, diabetes mellitus, and lithium carbonate. Arch Gen Psychiatry 1969; 21: 478–85
   Google Scholar
• Mellerup E T, Thomsen H G, Bjorum N, Rafaelsen O J. Lithium, weight gain, and serum insulin in manic-depressive patients. Acta Psychiatr Scand 1972; 48: 332–6
   Google Scholar
• Vendsborg P B, Rafaelsen O J. Lithium in man: effect on glucose tolerance and serum electrolytes. Acta Psychiatr Scand 1973; 49: 601–10
   Google Scholar
• Vieweg W V, Godleski L S, Hundley P L, Yank G R. Lithium, polyuria and abnormal diurnal weight gain in psychosis. Acta Psychiatr Scand 1988; 78: 510–4
   Google Scholar
• Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666–70
   PubMed Web of Science ®Google Scholar
• Garland E J. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol 1998; 12: 385–95
   PubMed Web of Science ®Google Scholar
• Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001; 24: 969–78
   PubMed Web of Science ®Google Scholar
• El-Khatib F, Rauchenzauner M, Lechleitner M, et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007; 16: 226–32
   PubMed Web of Science ®Google Scholar
• Millington D S, Bohan T P, Roe C R, Yergey A L, Liberato D J. Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta 1985; 145: 69–76
   PubMed Web of Science ®Google Scholar
• Laub M C. [Hyperammonemia in valproate therapy in children and adolescents]. Nervenarzt 1986; 57: 314–8
   PubMed Web of Science ®Google Scholar
• Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi J. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43: 514–7
   PubMed Web of Science ®Google Scholar
• Stephen L, Kwan P, Shapiro D, Dominiczak M, Brodie M. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001; 42: 1002–6
   PubMed Web of Science ®Google Scholar
• Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85: 114–8
   PubMed Web of Science ®Google Scholar
• Joffe R T, Post R M, Uhde T W. Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry 1986; 47: 313–4
   Google Scholar
• Khanna V, Arumugam S, Roy S, Mittra S, Bansal V S. Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opin Ther Targets 2008; 12: 81–90
   PubMed Web of Science ®Google Scholar
• Tata A L, Kockler D R. Topiramate for binge-eating disorder associated with obesity. Ann Pharmacother 2006; 40: 1993–7
   Google Scholar
• Post R M, Altshuler L L, Frye M A, et al. New findings from the Bipolar Collaborative Network: clinical implications for therapeutics. Curr Psychiatry Rep 2006; 8: 489–97
   PubMedGoogle Scholar
• Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs 2005; 19(suppl 1)1–93
   PubMed Web of Science ®Google Scholar
• Elmslie J L, Mann J I, Silverstone J T, Williams S M, Romans S E. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62: 486–91, quiz 492–3
   PubMed Web of Science ®Google Scholar
• van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342–8
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Scott J A, Turkin S, Kupfer D J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424–30
   PubMed Web of Science ®Google Scholar
• Garcia-Portilla M, Saiz P, Benabarre A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008; 106: 197–201
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Reiner Z, Milicic D. Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatr Danub 2007; 19: 270–81
   PubMed Web of Science ®Google Scholar
• Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9
   PubMed Web of Science ®Google Scholar
• Yumru M, Savas H A, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98: 247–52
   PubMed Web of Science ®Google Scholar
• Cardenas J, Frye M A, Marusak S L, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008; 106: 91–7
   PubMed Web of Science ®Google Scholar
• Teixeira P J, Rocha F L. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007; 29: 330–6
   PubMed Web of Science ®Google Scholar
• Luef G, Lechleitner M, Bauer G, Trinka E, Hengster P. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003; 55: 53–8
   PubMed Web of Science ®Google Scholar
• Isojarvi J, Laatikainen T, Knip M, Pakarinen A, Juntunen K, Myllyla V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579–84
   PubMed Web of Science ®Google Scholar
• Tsai S Y, Lee H C, Chen C C. Hyperinsulinaemia associated with beta-adrenoceptor antagonist in medicated bipolar patients during manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1038–43
   Google Scholar
• Cassidy F, Ritchie J, Carroll B. Plasma dexamethasone concentration and cortisol response during manic episodes. Biol Psychiatry 1998; 43: 747–54
   Google Scholar
• Brindley D N, Rolland Y. Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. Clin Sci (Lond) 1989; 77: 453–61
   PubMed Web of Science ®Google Scholar
• Zakrzewska K E, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, Jeanrenaud B. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997; 46: 717–9
   PubMed Web of Science ®Google Scholar
• Bjorntorp P. The regulation of adipose tissue distribution in humans. J Int Obes Relat Metab Disord 1996; 20: 291–302
   PubMed Web of Science ®Google Scholar
• DeFronzo R A, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94
   PubMed Web of Science ®Google Scholar
• Birkenaes A B, Birkeland K I, Engh J A, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008; 28: 132–7
   PubMed Web of Science ®Google Scholar
• Gergerlioglu H S, Savas H A, Celik A, et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology 2006; 53: 108–12
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus S C, Wilk J, West J C. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Serv 2006; 57: 205–11
   PubMed Web of Science ®Google Scholar
• Baptista T, Kin N, Beaulieu S, de Baptista E. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205–19
   PubMed Web of Science ®Google Scholar
• Rubi B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005; 280: 36824–32
   PubMed Web of Science ®Google Scholar
• Palik E, Birkas K D, Faludi G, Karadi I, Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005; 68(suppl 1)S60–4
   Google Scholar
• Theisen F M, Gebhardt S, Bromel T, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005; 112: 1411–6
   PubMed Web of Science ®Google Scholar
• Togo T, Hasegawa K, Miura S, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl) 2004; 172: 230–2
   PubMed Web of Science ®Google Scholar
• Sporn A L, Bobb A J, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005; 44: 925–33
   Google Scholar
• Wu R, Zhao J, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized clinical trial. JAMA 2008; 299: 185–93
   PubMed Web of Science ®Google Scholar